Results 41 to 50 of about 237 (77)

Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies. [PDF]

J Clin Tuberc Other Mycobact Dis
Timboe K, Jackson JB, Becker GL.
europepmc   +1 more source

A strategy to re-sensitise drug-resistant Gram-positive bacteria to oxazolidinone-class antibiotics. [PDF]

EBioMedicine
Zhang Q, Yang Y, Yang Y, Shang J, Su S, Gao P, Li XX, Liu Z, Kao RY, Ko BC, Thompson B, Zhao Q.   +11 more
europepmc   +1 more source

Research overview-2025: integrating scientific progress to accelerate global tuberculosis elimination. [PDF]

Front Tuberc
Moonan PK, Holtz TH.
europepmc   +1 more source

Neuromyelitis optica causing vision loss during TB treatment with sutezolid: evidence of aberrant immunity following infection. [PDF]

IJTLD Open
Glover NA, Paramo L, Giangregorio S, Sukwana B, Koele SE, Charalambous S, Ngwanto T, Mashatole S, Mudzengi D, Heinrich N, Svensson EM, Abdullah F, Churchyard G, Wallis RS.   +13 more
europepmc   +1 more source

Tuberculosis parenteral therapeutic regimens for critical patients or non-functional intestinal tract: Brief review and proposal of protocol. [PDF]

Braz J Infect Dis
Martins AC, Garcia MT, Resende MR.
europepmc   +1 more source

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists. [PDF]

Pathog Immun
Tunesi S, Bothamley G, Günther G, Kherabi Y, Kuksa L, Lange B, Lange C, Lorent N, Saluzzo F, Sester M, Iversen XES, Tebruegge M, Tweed C, Vasiliu A, Guglielmetti L, Tuberculosis Network European Trials group (TBnet).   +15 more
europepmc   +1 more source

Drug-Resistant Tuberculous Meningitis (DR-TBM) in a Low-Incidence Setting: Two Cases and an Evidence Review Highlighting Key Advances and Knowledge Gaps in Clinical Management. [PDF]

Open Forum Infect Dis
Boschung KF, Wong PHP, Werry D, Sekirov I, Turvey SL, Cook VJ, Johnston J, Connors WJA.   +7 more
europepmc   +1 more source

<i>tert</i>-Butyl Carbonate as a Nucleophile in Epoxide Ring Opening: A Cascade Synthesis of 5-(Hydroxymethyl)oxazolidin-2-one. [PDF]

J Org Chem
Lee K, Lee X, Zhou CY, Chu YL, Lin CK.
europepmc   +1 more source

Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China. [PDF]

BMC Infect Dis
Fu L, Shi H, Sun F, Wang W, Zhang P, Yang Q, Cai Y, Zhang X, Liang H, Wang Z, Xiong J, Chen X, Zhang W, Deng G.   +13 more
europepmc   +1 more source

Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon. [PDF]

Acta Pharm Sin B
Kufa M, Finger V, Kovar O, Soukup O, Torruellas C, Roh J, Korabecny J.   +6 more
europepmc   +1 more source